Meda completes acquisition of Valeant western and eastern European businesses
This article was originally published in Scrip
Executive Summary
Medahas completed its acquisition of Valeant Pharmaceutical's business in western and eastern Europe for $425 million, after certain closing adjustments raised the amount from the previously announced $392 million. The combined revenue of Valeant's products in western and eastern Europe last year was SEK520 million ($86 million; Scrip Online, August 8th, 2008). Through the acquisition, Meda hopes to enter Russia, as well as create significant market synergies with products in its pipeline.